These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23433400)

  • 1. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
    Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
    BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
    Thakur A; Scholler J; Schalk DL; June CH; Lum LG
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
    Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
    Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
    Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B
    Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting bladder cancer using activated T cells armed with bispecific antibodies.
    Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M
    Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
    Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
    Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
    Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
    J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
    Lum LG; Sen M
    Acta Haematol; 2001; 105(3):130-6. PubMed ID: 11463985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
    Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
    Front Oncol; 2020; 10():544. PubMed ID: 32432032
    [No Abstract]   [Full Text] [Related]  

  • 19. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
    Thakur A; Scholler J; Kubicka E; Bliemeister ET; Schalk DL; June CH; Lum LG
    Front Immunol; 2021; 12():690437. PubMed ID: 34290709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.
    Thakur A; Sorenson C; Norkina O; Schalk D; Ratanatharathorn V; Lum LG
    Transfusion; 2012 Jan; 52(1):63-75. PubMed ID: 21745212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.